Paper40969871
Next-Generation Lipid Prodrugs Orally Deliver Tenofovir via Enhanced Chylomicron Incorporation.
Gold HB and 17 others. ACS Pharmacol Transl Sci, 2025. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. Next-Generation Lipid Prodrugs Orally Deliver Tenofovir via Enhanced Chylomicron Incorporation. Papers, record 40969871. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40969871
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Next-Generation Lipid Prodrugs Orally Deliver Tenofovir via Enhanced Chylomicron Incorporation.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants5
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| T32 GM145445 | NIGMS NIH HHS | United States | T32GM145445 | PubMed | NIH RePORTER |
| R01 AI128837 | NIAID NIH HHS | United States | R01AI128837 | PubMed and NIH | NIH RePORTER |
| UL1 TR000454 | NCATS NIH HHS | United States | UL1TR000454 | PubMed | NIH RePORTER |
| S10 RR025679 | NCRR NIH HHS | United States | S10RR025679 | PubMed | NIH RePORTER |
| R01 AI174979 | NIAID NIH HHS | United States | R01AI174979 | PubMed and NIH | NIH RePORTER |
References62
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35496278 | Triglyceride-Mimetic Prodrugs of Buprenorphine Enhance Oral Bioavailability via Promotion of Lymphatic Transport. | Front Pharmacol | 2022 | https://conductscience.org/library/papers/35496278 | PubMed |
| 2 | 35058937 | Pulmonary Immune Dysregulation and Viral Persistence During HIV Infection. | Front Immunol | 2021 | https://conductscience.org/library/papers/35058937 | PubMed |
| 3 | 9918041 | Fast ultracentrifugation methods for the separation of plasma lipoproteins. | Methods Mol Biol | 1998 | https://conductscience.org/library/papers/9918041 | PubMed |
| 4 | 36374157 | Placing CF2 in the Center: Major Physicochemical Changes Upon a Minor Structural Alteration in Gem-Difunctional Compounds. | Chemistry | 2023 | https://conductscience.org/library/papers/36374157 | PubMed |
| 5 | 11093912 | A new method for the study of chylomicron kinetics in vivo. | Am J Physiol Endocrinol Metab | 2000 | https://conductscience.org/library/papers/11093912 | PubMed |
| 6 | 34896450 | Smart design approaches for orally administered lipophilic prodrugs to promote lymphatic transport. | J Control Release | 2022 | https://conductscience.org/library/papers/34896450 | PubMed |
| 7 | 35179893 | Synthesis and Evaluation of Novel Tetrahydronaphthyridine CXCR4 Antagonists with Improved Drug-like Profiles. | J Med Chem | 2022 | https://conductscience.org/library/papers/35179893 | PubMed |
| 8 | 21493074 | Synthesis, metabolic stability and antiviral evaluation of various alkoxyalkyl esters of cidofovir and 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine. | Bioorg Med Chem | 2011 | https://conductscience.org/library/papers/21493074 | PubMed |
| 9 | 38004512 | Development of a Novel In Vitro Model to Study Lymphatic Uptake of Drugs via Artificial Chylomicrons. | Pharmaceutics | 2023 | https://conductscience.org/library/papers/38004512 | PubMed |
| 10 | 3594676 | Synthesis and biological activity of fluorine-modified platelet activating factors. | Chem Pharm Bull (Tokyo) | 1987 | https://conductscience.org/library/papers/3594676 | PubMed |
| 11 | 10929917 | Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. | Clin Ther | 2000 | https://conductscience.org/library/papers/10929917 | PubMed |
| 12 | 11033424 | Rationale and applications of lipids as prodrug carriers. | Eur J Pharm Sci | 2000 | https://conductscience.org/library/papers/11033424 | PubMed |
| 13 | 28885375 | Tenofovir alafenamide nephrotoxicity in an HIV-positive patient: A case report. | Medicine (Baltimore) | 2017 | https://conductscience.org/library/papers/28885375 | PubMed |
| 14 | 28540164 | Understanding peroral absorption: regulatory aspects and contemporary approaches to tackling solubility and permeability hurdles. | Acta Pharm Sin B | 2017 | https://conductscience.org/library/papers/28540164 | PubMed |
| 15 | 38365068 | Novel solid self-emulsifying drug delivery system to enhance oral bioavailability of cabazitaxel. | Int J Pharm | 2024 | https://conductscience.org/library/papers/38365068 | PubMed |
| 16 | 17646420 | Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections. | Antimicrob Agents Chemother | 2007 | https://conductscience.org/library/papers/17646420 | PubMed |
| 17 | 39240093 | Oral pharmacokinetics and efficacy of oral phospholipid remdesivir nucleoside prodrugs against SARS-CoV-2 in mice. | Antimicrob Agents Chemother | 2024 | https://conductscience.org/library/papers/39240093 | PubMed |
| 18 | 30554119 | Cabazitaxel and silibinin co-encapsulated cationic liposomes for CD44 targeted delivery: A new insight into nanomedicine based combinational chemotherapy for prostate cancer. | Biomed Pharmacother | 2019 | https://conductscience.org/library/papers/30554119 | PubMed |
| 19 | 16279790 | Synthesis and biological activity of anticancer ether lipids that are specifically released by phospholipase A2 in tumor tissue. | J Med Chem | 2005 | https://conductscience.org/library/papers/16279790 | PubMed |
| 20 | 30025212 | Targeting the intestinal lymphatic system: a versatile path for enhanced oral bioavailability of drugs. | Expert Opin Drug Deliv | 2018 | https://conductscience.org/library/papers/30025212 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42965765 | Intervening in Adipocyte Senescence: Lipid Prodrugs as an Emerging Strategy for Metabolic Disease Treatment. | Curr Med Sci | 2026 | https://conductscience.org/library/papers/42965765 | PubMed |
| 42280151 | Fatty Acids in Cancer Therapy: Chemical Conjugates, Nanocarriers, and Therapeutic Opportunities. | Molecules | 2026 | https://conductscience.org/library/papers/42280151 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40969871
GET https://conductscience.org/api/papers/v1/40969871/references?page=2